Clinical Trial News and Research

RSS

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance (empagliflozin) in more than 7,000 adults with type 2 diabetes (T2D) at high risk for CV events.

20 Aug 2015

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.

19 Aug 2015

UC Davis researchers set out to identify biomarkers for early diagnosis of lung cancer

Despite decades of warnings about smoking, lung cancer is still the second-most common cancer and the leading cause of death from cancer in the U.S. Patients are often diagnosed only when their disease is already at an advanced stage and hard to treat. Researchers at the West Coast Metabolomics Center at UC Davis are trying to change that, by identifying biomarkers that could be the basis of early tests for lung cancer.

19 Aug 2015

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential. Palatin's lead product under development is bremelanotide for the treatment of female sexual dysfunction (FSD).

19 Aug 2015

Loyola implants new percutaneous aortic heart valve that does not require open surgery

Loyola University Medical Center is the first center in Illinois to implant a new percutaneous aortic heart valve that does not require open heart surgery.

19 Aug 2015

NIH grants Clinical and Translational Science Award to UC San Diego

The Clinical and Translational Research Institute (CTRI) at University of California, San Diego has received a five-year Clinical and Translational Science Award (CTSA) for approximately $52 million from the National Center for Advancing Translational Science, part of the National Institutes of Health.

19 Aug 2015

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Intarcia Therapeutics, Inc. today announced positive top-line results from its 52-week Phase 3 FREEDOM-2 clinical trial to determine the comparative efficacy of the company's late-stage investigational candidate ITCA 650 to Merck's Januvia in reducing HbA1c in patients with type 2 diabetes following a year of treatment.

18 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

VA study examines use of medicinal maggots to heal diabetic foot ulcers

Maggot, or larval, therapy has been around since ancient times as a way to heal wounds. Now, the method has gone high-tech--in some ways--and it's being tested in a rigorous clinical trial at the Malcom Randall Veterans Affairs (VA) Medical Center in Gainesville, Fla. Recruitment is now underway.

18 Aug 2015

Vitamin D supplements may help reduce risk of falls in homebound elderly

Every year falls affect approximately one in three older adults living at home, with approximately one in 10 falls resulting in serious injury. Even if an injury does not occur, the fear of falling can lead to reduced activity and a loss of independence.

18 Aug 2015

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

Boehringer Ingelheim announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto® Respimat® (tiotropium/olodaterol) provides consistent, clinically meaningful improvements in quality of life versus placebo in patients with COPD

17 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

GlySens secures FDA approval to extend current human clinical evaluation of fully implanted CGM system

GlySens Incorporated announced today that it has secured FDA approval for extending the current human clinical evaluation of its fully implantable continuous glucose monitoring system (the ICGM System) from the originally approved six-month duration to the system's commercially-intended operational duration of twelve months.

17 Aug 2015

Algorithm encompassing clinical and genetic factors predicts PD

Researchers have devised a model that distinguishes patients with Parkinson’s disease from those without the condition without relying on motor features.

14 Aug 2015

‘Medical foods’ for patients with rare IEMs may cause harm when not carefully managed

Many "medical foods" are designed to help manage patients with rare inborn errors of metabolism (IEMs), and can help prevent serious and life-threatening complications. However, such special foods may cause harm in some patients when their use is not carefully monitored and managed, according to a research team led by scientists at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health.

14 Aug 2015

CASI reports financial results for second quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and six months ended June 30, 2015.

14 Aug 2015

Rush researchers explore new stem cell therapy to treat spinal cord injuries

Researchers at Rush University Medical Center are exploring a new therapy using stem cells to treat spinal cord injuries within the first 14 to 30 days of injury. Rush is only the second center in the country currently studying this new approach.

14 Aug 2015

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.

13 Aug 2015

Clinical Trial News and Research

EMPA-REG OUTCOME trial demonstrates superiority of Jardiance in T2D patients at risk for CV events

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine

UC Davis researchers set out to identify biomarkers for early diagnosis of lung cancer

Palatin applauds FDA's approval of flibanserin for women living with hypoactive sexual desire disorder

Loyola implants new percutaneous aortic heart valve that does not require open surgery

NIH grants Clinical and Translational Science Award to UC San Diego

Intarcia Therapeutics announces positive top-line results from ITCA 650 Phase 3 FREEDOM-2 clinical trial

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

VA study examines use of medicinal maggots to heal diabetic foot ulcers

Vitamin D supplements may help reduce risk of falls in homebound elderly

New OTEMTO phase three results show potential improvement to quality of life for COPD patients

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

GlySens secures FDA approval to extend current human clinical evaluation of fully implanted CGM system

Algorithm encompassing clinical and genetic factors predicts PD

‘Medical foods’ for patients with rare IEMs may cause harm when not carefully managed

CASI reports financial results for second quarter 2015

Rush researchers explore new stem cell therapy to treat spinal cord injuries

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer